Nintedanib vs Pirfenidone: A Complete Comparison for IPF Patients

Nintedanib (brand name Ofev) and pirfenidone (brand name Esbriet) are the two most widely prescribed drugs for idiopathic pulmonary fibrosis. Both were approved in 2014 and both slow disease progression. But they work differently, have different side effects, and may suit different patient profiles. This article provides a detailed comparison to help patients and physicians make informed decisions.

Mechanism of Action

Nintedanib is a triple tyrosine kinase inhibitor. It blocks FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor receptor), and VEGFR (vascular endothelial growth factor receptor). By inhibiting these signaling pathways, nintedanib reduces fibroblast proliferation, migration, and transformation into myofibroblasts.

Pirfenidone has a less clearly defined mechanism. It reduces TGF-beta expression, inhibits collagen synthesis, and has anti-inflammatory and antioxidant properties. It appears to work through multiple pathways rather than a single molecular target.

Efficacy

Both drugs reduce the rate of FVC decline by approximately 50% compared to placebo. The INPULSIS trials (nintedanib) and ASCEND trial (pirfenidone) demonstrated this effect over 52 weeks. Neither drug stops FVC decline completely, and neither reverses existing fibrosis.

Head-to-head comparison data is limited. No large randomized trial has directly compared the two drugs. Retrospective analyses and real-world studies suggest comparable efficacy, though some observational data indicates pirfenidone may have a slight mortality benefit. The evidence is not conclusive.

Side Effects

Nintedanib causes diarrhea in approximately 62% of patients. This is the most common side effect and is typically manageable with loperamide and dose reduction. Liver enzyme elevation occurs in approximately 14% of patients. Nausea and decreased appetite are also reported.

Pirfenidone causes nausea in approximately 36% of patients, rash in 30%, and photosensitivity (increased sensitivity to sunlight) in 12%. Patients on pirfenidone should use sunscreen and avoid prolonged sun exposure. GI symptoms tend to be milder than with nintedanib, but the photosensitivity is a unique concern.

Cost

Both drugs are expensive. In the United States, the list price for nintedanib is approximately $8,000 to $10,000 per month. Pirfenidone costs approximately $8,000 to $9,000 per month. Insurance coverage, co-pay assistance programs, and generic availability (pirfenidone went generic in some markets) significantly affect out-of-pocket cost.

PF-Atlas provides a Drug Access Guide with country-specific pricing, patient assistance programs, and insurance appeal letter templates.

Which Drug Is Better for Different Patients

For patients with pre-existing GI issues (irritable bowel syndrome, frequent diarrhea), pirfenidone may be better tolerated despite its own GI side effects. For patients with sun-sensitive skin or outdoor occupations, nintedanib avoids the photosensitivity risk. For patients who prefer a simpler dosing schedule, nintedanib requires only 2 pills per day versus 9 for pirfenidone.

For patients with liver disease, pirfenidone may be preferred as nintedanib carries a higher risk of liver enzyme elevation. For patients on anticoagulants, nintedanib requires monitoring due to its anti-VEGFR activity and potential bleeding risk.

In practice, the choice often depends on individual tolerability. Many patients try one drug first and switch to the other if side effects are intolerable. The INJOURNEY trial demonstrated that adding pirfenidone to nintedanib is feasible, though GI side effects increase.

The Emerging Alternative: Nerandomilast

Nerandomilast (BI 1015550), approved by the FDA in October 2025, offers a third option. It inhibits PDE4B, a phosphodiesterase involved in inflammation and TGF-beta signaling. The FIBRONEER-IPF trial showed approximately 63% reduction in FVC decline, numerically superior to both nintedanib and pirfenidone. GI tolerability data is still being collected. PF-Atlas models nerandomilast alongside 18 other drugs in its combination solver.